- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 271/06 - 1,2,4-OxadiazolesHydrogenated 1,2,4-oxadiazoles
Patent holdings for IPC class C07D 271/06
Total number of patents in this class: 954
10-year publication summary
|
99
|
111
|
104
|
100
|
74
|
60
|
64
|
59
|
40
|
27
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| BASF SE | 21334 |
62 |
| Syngenta Participations AG | 1474 |
36 |
| Receptos LLC | 59 |
26 |
| Bristol-myers Squibb Company | 4747 |
25 |
| PTC Therapeutics, Inc. | 464 |
21 |
| PI Industries Ltd | 209 |
21 |
| Aurigene Oncology Limited | 132 |
20 |
| Syngenta Crop Protection AG | 6804 |
18 |
| King Faisal University | 936 |
17 |
| The Scripps Research Institute | 1345 |
15 |
| Cytokinetics, Inc. | 251 |
14 |
| Sumitomo Chemical Company, Limited | 8992 |
12 |
| Merck Sharp & Dohme LLC | 3734 |
12 |
| Modernatx, Inc. | 1278 |
10 |
| Calico Life Sciences LLC | 121 |
10 |
| Bayer Cropscience AG | 1820 |
9 |
| University of Notre Dame du Lac | 614 |
9 |
| Allergan, Inc. | 2145 |
8 |
| Bayer AG | 3566 |
8 |
| Shionogi & Co., Ltd. | 889 |
8 |
| Other owners | 593 |